Sunday 18 October 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
6.04
0.64
−9.58%
Follow AGEN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 3 | 2 | 7 | 2 | 4 | 2 | 2 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(14.16) | (15.67) | (10.06) | (6.06) | (2.17) | (10.29) | (11.54) | (14.25) | (11.52) | (8.73) |
P/S ratio |
0.82 | 0.57 | 1.83 | 6.77 | 2.45 | 6.11 | 3.59 | 7.03 | 7.97 | 15.75 |
Altman Z″-Score (non-manufacturers) |
(38.05) | (40.73) | (27.06) | (16.13) | (7.47) | (26.96) | (32.14) | (34.50) | (28.78) | (21.50) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
12.57 | (5.29) | 1.93 | 0.09 | (1.17) | (4.63) | 0.44 | (3.59) | (3.44) | (3.89) |
P/Operating CF |
(5.62) | (2.05) | (7.09) | (14.02) | (31.55) | (15.12) | (16.96) | (7.22) | (13.22) | (22.06) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 15.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 49.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1.39 | 0.50 | 1.43 | 4.93 | 1.45 | 5.20 | 3.27 | 5.95 | 10.37 | 18.15 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 13.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.05) | (0.33) | (1.00) | (2.76) | 42.39 | (3.29) | (26.30) | (1.67) | (4.72) | (5.12) |
EV/FCF |
(2.06) | (0.32) | (0.97) | (2.34) | (23.87) | (3.21) | (21.05) | (1.63) | (4.57) | (4.43) |
Quick Ratio |
0.03 | 0.18 | 0.40 | 1.04 | 1.97 | 0.78 | 0.64 | 0.79 | 1.09 | 2.15 |
Current Ratio |
0.41 | 0.21 | 0.44 | 1.13 | 2.12 | 0.88 | 0.71 | 1.10 | 1.30 | 2.24 |
Net Debt/EBITDA |
(4.10) | 0.07 | 0.43 | 1.04 | (9.02) | 0.73 | 0.75 | 0.34 | (1.05) | (0.53) |
Debt/Assets |
19.69% | 14.66% | 4.11% | 3.18% | 2.91% | 9.19% | 9.03% | 9.79% | 117.79% | 83.25% |
Debt/Equity |
(0.16) | (0.11) | (0.09) | (0.24) | 0.28 | (0.09) | (0.06) | (0.08) | (2.15) | (3.34) |
Asset Turnover |
0.50 | 0.38 | 0.43 | 0.22 | 0.87 | 0.48 | 1.03 | 0.27 | 0.29 | 0.11 |
Operating CF/Net income |
764.31 | 0.70 | 0.91 | 0.80 | (0.42) | 0.77 | 0.17 | 0.82 | 0.78 | 0.63 |
Capex/Depreciation |
0.04 | (0.04) | (0.49) | (4.47) | (4.15) | (0.48) | (0.70) | (0.57) | (0.50) | (2.53) |
Interest Coverage |
(0.36) | (1.02) | (1.63) | (2.90) | 0.39 | (1.92) | (1.69) | (4.90) | (5.50) | (6.21) |
| 0.03% | 100.01% | 242.00% | 6,300.19% | 29.51% | 81.80% | 53.15% | 127.73% | 210.36% | (805.04%) | |
| (0.04%) | (84.20%) | (67.62%) | (50.09%) | (7.09%) | (97.94%) | (73.95%) | (116.37%) | (81.86%) | (63.72%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (240.08%) | (444.11%) |
Return on Tangible Assets |
0.06% | 408.01% | 2,445.07% | (140.14%) | (10.27%) | (1,694.48%) | 1,154.01% | (501.85%) | (279.25%) | (167.16%) |
Average Days of Receivables |
22.41 | 1.44 | 60.33 | 10.21 | 1.87 | 4.79 | 39.63 | 9.31 | 9.66 | 183.56 |
Research and Development Expense of Revenue |
69.48% | 150.32% | 150.06% | 190.45% | 60.41% | 161.75% | 112.19% | 338.73% | 270.83% | 420.72% |
Selling, General and Administrative Expense of Revenue |
47.63% | 69.47% | 50.37% | 82.64% | 25.83% | 67.16% | 30.68% | 101.51% | 78.69% | 146.75% |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.09 | 0.08 | 0.07 | 0.17 | 0.22 | 0.26 | 0.27 | 0.25 |
Share Based Compensation of Revenue |
12.06% | 16.81% | 14.63% | 18.71% | 6.62% | 11.81% | 6.59% | 20.73% | 28.99% | 58.42% |
Graham Net Nets |
(3.98) | (8.28) | (1.22) | (0.38) | (0.12) | (0.58) | (0.56) | (0.91) | (0.41) | (0.29) |
Graham Number |
9.17 | 58.56 | 51.47 | 37.22 | 0.00 | 108.66 | 110.39 | 143.89 | 91.97 | 77.10 |
Earnings Yield |
(12.74%) | (389.78%) | (88.75%) | (33.54%) | (4.43%) | (34.29%) | (19.78%) | (62.51%) | (35.12%) | (36.01%) |
Free Cash Flow Yield |
(82.30%) | (270.02%) | (80.61%) | (31.11%) | (2.49%) | (26.48%) | (4.33%) | (52.06%) | (28.44%) | (26.02%) |
Revenue per Share |
3.84 | 4.82 | 8.74 | 6.96 | 25.83 | 10.22 | 22.23 | 6.64 | 8.71 | 5.19 |
Operating CF per Share |
(2.60) | (7.37) | (12.53) | (12.45) | 0.89 | (16.13) | (2.77) | (23.67) | (19.15) | (18.37) |
Capex per Share |
0.01 | (0.03) | (0.37) | (2.21) | (2.46) | (0.40) | (0.69) | (0.65) | (0.61) | (2.88) |
Free Cash Flow per Share |
(2.58) | (7.40) | (12.90) | (14.65) | (1.57) | (16.53) | (3.46) | (24.32) | (19.76) | (21.24) |
Cash per Share |
0.10 | 1.88 | 4.25 | 13.73 | 26.81 | 11.58 | 9.16 | 9.58 | 12.23 | 17.56 |
Shareholders Equity per Share |
(9.34) | (14.27) | (8.29) | (3.90) | 4.19 | (24.52) | (34.28) | (31.51) | (15.41) | (8.99) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(9.34) | (14.27) | (8.29) | (3.90) | 4.19 | (24.52) | (34.28) | (31.51) | (15.41) | (8.99) |
Free Cash Flow |
(76.84) | (158.87) | (230.79) | (206.44) | (18.01) | (142.56) | (23.34) | (134.69) | (97.23) | (92.48) |
Working Capital |
(190.05) | (175.83) | (143.48) | 24.17 | 175.03 | (16.10) | (35.67) | 6.75 | 17.12 | 50.46 |
Capital Expenditures |
0.35 | (0.55) | (6.59) | (31.06) | (28.16) | (3.47) | (4.66) | (3.59) | (3.00) | (12.52) |
Net Current Asset Value |
(371.22) | (487.12) | (349.88) | (255.34) | (86.07) | (312.23) | (300.14) | (236.14) | (140.66) | (104.80) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 16.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 | 0.04 | 0.32 | 0.10 | 0.04 | 0.03 | 0.10 | 0.07 | 0.55 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 28.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.65 | 0.11 | 0.10 | 0.05 | 0.11 | 0.27 | 0.25 | 0.25 | 0.23 | 0.19 |
Cash ROIC |
33.38% | 68.24% | 388.82% | (136.16%) | (4.89%) | 155.10% | 15.01% | 124.56% | (65.96%) | (55.05%) |
Accounts Receivable Turnover |
30.79 | 7.89 | 10.94 | 46.03 | 221.06 | 10.11 | 17.42 | 35.50 | 6.87 | 2.13 |
Accounts Payable Turnover |
0.01 | 0.01 | 0.06 | 0.30 | 0.15 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
29,638.21 | 46,165.74 | 7,209.19 | 1,413.96 | 3,206.74 | 2,643.88 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
3.71 | 13.12 | 14.29 | 2.13 | 1.34 | 8.73 | 8.62 | 1.04 | 6.24 | 10.58 |
Average Payables |
72.23 | 61.46 | 51.19 | 35.71 | 23.75 | 15.29 | 13.59 | 10.86 | 6.76 | 4.96 |
Average Inventory |
— | — | — | — | — | — | — | 0.07 | 0.08 | 0.09 |
Average Assets |
226.53 | 270.09 | 363.73 | 439.76 | 340.24 | 184.92 | 145.87 | 137.40 | 147.69 | 199.61 |
Average Common Equity |
(292.14) | (227.40) | (101.64) | (3.50) | (81.79) | (221.42) | (202.94) | (125.18) | (57.47) | 15.80 |
Columns are period end dates